CARTISTEM
approveddrug program · high · Wed Mar 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat knee cartilage lesions and osteoarthritis, with evaluation of pain, function, and possible disease-modifying effects on osteoarthritis progression.
Allogeneic human umbilical cord blood-derived mesenchymal stem cells formulated with cross-linked sodium hyaluronate hydrogel; evaluated against surgical debridement and in cartilage-regeneration clinical studies.
Phase 3 pivotal trial comparing CARTISTEM with surgical comparator for knee cartilage lesions and osteoarthritis was published in ClinicalTrials.gov on 2026-03-11; product was launched in Korea in 2012.
Commercialized as a regulatory-approved allogeneic hUCB-MSC product for knee osteoarthritis; multiple 2023-2025 publications report clinical and MRI/cartilage-regeneration outcomes after hUCB-MSC implantation.
NEUROSTEM
exploratorydrug program · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a central nervous system-directed stem cell therapy relevant to Alzheimer's disease and optimize safety after intracerebroventricular delivery.
Human mesenchymal stem cells administered intracerebroventricularly; publication analyzed CSF from Alzheimer's disease patients treated with saline or hMSCs and investigated MMP9-related mechanisms in vitro and in 5xFAD mice.
2026 publication reported MMP9-driven transient inflammation findings from Alzheimer's disease patient CSF and preclinical mechanistic studies; ClinicalTrials.gov identifier NCT02054208 was cited.
MSC administration increased MMP9 levels in CSF; MMP9 knockdown altered MSC migration and was associated with increased local immune activation in mice, suggesting MMP9-dependent processes are important early after CNS transplantation.
Umbilical cord blood plasma cellular repair and senescence suppression research
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate whether human umbilical cord blood plasma enhances cellular repair and suppresses senescence under oxidative stress.
Human dermal fibroblast research under oxidative stress using umbilical cord blood plasma.
2025 publication on cellular repair and senescence suppression in human dermal fibroblasts.
The supplied title indicates enhanced cellular repair and senescence suppression in human dermal fibroblasts under oxidative stress.
SMUP-IA-01
phase 2drug program · high · Mon Mar 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat knee osteoarthritis and assess long-term safety and exploratory efficacy.
Investigational intra-articular therapy for patients with Kellgren-Lawrence grade 2 or 3 knee osteoarthritis; studied in Phase I dose-escalation, Phase II efficacy/safety, and long-term follow-up trials.
Long-term follow-up study of subjects from the Phase II trial NCT05182034 was published on ClinicalTrials.gov on 2023-03-20 and follows subjects up to 60 months.
PNEUMOSTEM
phase 2drug program · high · Fri Jul 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Prevent and treat severe bronchopulmonary dysplasia in premature infants and assess long-term safety and efficacy.
PNEUMOSTEM versus placebo in premature infants with severe BPD, followed by a long-term follow-up study to 60 months corrected age.
Long-term follow-up of subjects who completed the Phase II PNEUMOSTEM trial was published on ClinicalTrials.gov on 2019-07-05.
NGF-574H
exploratoryconsumer product · high · Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and efficacy for hair growth in adults with androgenic alopecia.
Clinical study of a cosmetic investigational product containing NGF-574H in Asian adults with androgenic alopecia.
ClinicalTrials.gov record published on 2018-10-02.
CELLTREE cord blood banking
approvedother · high
Provide cord blood banking services as part of MEDIPOST's business.
Cord blood banking service.
Listed as an active MEDIPOST business line in the supplied site analysis.
MEDIPOST CDMO services
approvedplatform · medium
Provide CDMO services related to MEDIPOST's regenerative medicine and stem-cell capabilities.
Contract development and manufacturing services.
Listed as an active MEDIPOST business line in the supplied site analysis.
MOVITA nutritional supplements
approvedconsumer product · high
Provide nutritional supplement products as part of MEDIPOST's business.
Nutritional supplement consumer products.
Listed as an active MEDIPOST business line in the supplied site analysis.
SMUP-IV-01
undiscloseddrug program · medium
Develop a stem-cell therapeutic program listed in MEDIPOST's pipeline.
Not disclosed in the supplied material beyond pipeline listing.
Listed in MEDIPOST pipeline.
